|
Mutation Information
|
Mutation Site
|
M250I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
entecavir (ETV);lamivudine (LAM) |
Literature Information
|
PubMed PMID
|
17178796
|
|
Disease
|
Chronic hepatitis B
|
|
Published Year
|
2007 |
|
Journal
|
Antimicrobial agents and chemotherapy |
|
Title
|
Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. |
|
Author
|
Tenney DJ,Rose RE,Baldick CJ,Levine SM,Pokornowski KA,Walsh AW,Fang J,Yu CF,Zhang S,Mazzucco CE,Eggers B,Hsu M,Plym MJ,Poundstone P,Yang J,Colonno RJ |
|
Evidence
|
The T184, S202, or M250 substitution was found in LVDr HBV at baseline in 6% of patients and emerged in isolates from another 11/187 (6%) and 12/151 (8%) ETV-treated patients by Weeks 48 and 96, respectively
|
|
|
HBV Mutation Detail Information